Literature DB >> 32914259

Sphingosine 1-Phosphate Receptors in Cerebral Ischemia.

Bhakta Prasad Gaire1, Ji Woong Choi2.   

Abstract

Sphingosine 1-phosphate (S1P) is an important lipid biomolecule that exerts pleiotropic cellular actions as it binds to and activates its five G-protein-coupled receptors, S1P1-5. Through these receptors, S1P can mediate diverse biological activities in both healthy and diseased conditions. S1P is produced by S1P-producing enzymes, sphingosine kinases (SphK1 and SphK2), and is abundantly present in different organs, including the brain. The medically important roles of receptor-mediated S1P signaling are well characterized in multiple sclerosis because FTY720 (Gilenya™, Novartis), a non-selective S1P receptor modulator, is currently used as a treatment for this disease. In cerebral ischemia, its role is also notable because of FTY720's efficacy in both rodent models and human patients with cerebral ischemia. In particular, some of the S1P receptors, including S1P1, S1P2, and S1P3, have been identified as pathogenic players in cerebral ischemia. Other than these receptors, S1P itself and S1P-producing enzymes have been shown to play certain roles in cerebral ischemia. This review aims to compile the current updates and overviews about the roles of S1P signaling, along with a focus on S1P receptors in cerebral ischemia, based on recent studies that used in vivo rodent models of cerebral ischemia.

Entities:  

Keywords:  Cerebral ischemia; S1P receptors; Sphingosine 1-phosphate

Year:  2020        PMID: 32914259     DOI: 10.1007/s12017-020-08614-2

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  92 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

2.  Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma.

Authors:  Salvatore Cuzzocrea; Timothy Doyle; Michela Campolo; Irene Paterniti; Emanuela Esposito; Susan A Farr; Daniela Salvemini
Journal:  J Neurotrauma       Date:  2018-04-17       Impact factor: 5.269

3.  Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.

Authors:  Tobias Bobinger; Anatol Manaenko; Petra Burkardt; Vanessa Beuscher; Maximilian I Sprügel; Sebastian S Roeder; Tobias Bäuerle; Lisa Seyler; Armin M Nagel; Ralf A Linker; Tobias Engelhorn; Arnd Dörfler; S V Horsten; Stefan Schwab; Hagen B Huttner
Journal:  Stroke       Date:  2019-09-27       Impact factor: 7.914

4.  Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice.

Authors:  Vanessa H Brait; Gema Tarrasón; Amadeu Gavaldà; Núria Godessart; Anna M Planas
Journal:  Stroke       Date:  2016-11-08       Impact factor: 7.914

Review 5.  Astrocytes: Key Regulators of Neuroinflammation.

Authors:  Emanuela Colombo; Cinthia Farina
Journal:  Trends Immunol       Date:  2016-07-19       Impact factor: 16.687

Review 6.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms.

Authors:  Michelle L Block; Luigi Zecca; Jau-Shyong Hong
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

7.  Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.

Authors:  Alaa S Awad; Hong Ye; Liping Huang; Li Li; Frank W Foss; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa
Journal:  Am J Physiol Renal Physiol       Date:  2006-01-10

Review 8.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

9.  Distribution of sphingosine kinase activity and mRNA in rodent brain.

Authors:  Nicolas Blondeau; Yushuan Lai; Sarah Tyndall; Margherita Popolo; Kamil Topalkara; James K Pru; Ling Zhang; Hyunghwan Kim; James K Liao; Kan Ding; Christian Waeber
Journal:  J Neurochem       Date:  2007-07-10       Impact factor: 5.372

10.  Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.

Authors:  Stephanie S Dusaban; Jerold Chun; Hugh Rosen; Nicole H Purcell; Joan Heller Brown
Journal:  J Neuroinflammation       Date:  2017-06-02       Impact factor: 8.322

View more
  5 in total

Review 1.  Microglia as the Critical Regulators of Neuroprotection and Functional Recovery in Cerebral Ischemia.

Authors:  Bhakta Prasad Gaire
Journal:  Cell Mol Neurobiol       Date:  2021-08-30       Impact factor: 4.231

Review 2.  Nitric Oxide as a Target for Phytochemicals in Anti-Neuroinflammatory Prevention Therapy.

Authors:  Lalita Subedi; Bhakta Prasad Gaire; Amna Parveen; Sun-Yeou Kim
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 3.  Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond.

Authors:  Shuo-Qi Zhang; Jun Xiao; Man Chen; Luo-Qi Zhou; Ke Shang; Chuan Qin; Dai-Shi Tian
Journal:  Front Cell Neurosci       Date:  2021-11-30       Impact factor: 5.505

Review 4.  Involvement of Ceramide Metabolism in Cerebral Ischemia.

Authors:  Alberto Ouro; Clara Correa-Paz; Elena Maqueda; Antía Custodia; Marta Aramburu-Núñez; Daniel Romaus-Sanjurjo; Adrián Posado-Fernández; María Candamo-Lourido; Maria Luz Alonso-Alonso; Pablo Hervella; Ramón Iglesias-Rey; José Castillo; Francisco Campos; Tomás Sobrino
Journal:  Front Mol Biosci       Date:  2022-04-20

Review 5.  Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases.

Authors:  Antía Custodia; Daniel Romaus-Sanjurjo; Marta Aramburu-Núñez; Diego Álvarez-Rafael; Laura Vázquez-Vázquez; Javier Camino-Castiñeiras; Yago Leira; Juan Manuel Pías-Peleteiro; José Manuel Aldrey; Tomás Sobrino; Alberto Ouro
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.